Glioma Classification & Molecular Markers
The WHO 2021 Classification of CNS Tumors represents a paradigm shift in how diffuse gliomas are diagnosed and categorized. Rather than relying primarily on histologic appearance, the updated classification mandates an integrated diagnosis combining histologic features with specific molecular biomarkers. This molecular-first approach has fundamentally redefined adult-type diffuse gliomas into three distinct entities with profoundly different biology, treatment responses, and prognoses. Understanding these molecular distinctions is now essential for every neurologist involved in the care of brain tumor patients, as classification directly drives treatment decisions and prognostic counseling.
Bottom Line
- Integrated diagnosis is mandatory: WHO 2021 requires molecular markers alongside histology — a purely histologic diagnosis of “diffuse glioma” is no longer acceptable
- Three adult-type diffuse gliomas: Astrocytoma IDH-mutant, Oligodendroglioma IDH-mutant 1p/19q-codeleted, and Glioblastoma IDH-wildtype — each with distinct molecular signatures
- IDH status is the single most important prognostic marker: IDH-mutant gliomas have dramatically better survival than IDH-wildtype tumors regardless of histologic grade
- Molecular features can override histology: A histologically low-grade diffuse glioma that is IDH-wildtype with TERT promoter mutation, +7/−10, or EGFR amplification is classified as glioblastoma (grade 4)
- CDKN2A/B homozygous deletion: Upgrades an IDH-mutant astrocytoma to grade 4, independent of histologic features
- MGMT promoter methylation: Predicts temozolomide response in glioblastoma and is critical for treatment planning, especially in elderly patients
WHO 2021 Classification: The Molecular Revolution
Prior WHO classifications (2007, 2016) relied heavily on histologic features such as cellularity, nuclear atypia, mitotic activity, microvascular proliferation, and necrosis to define glioma subtypes and grades. The 2016 edition introduced molecular parameters but allowed “NOS” (not otherwise specified) diagnoses when molecular testing was unavailable. The 2021 revision goes further: molecular testing is now required for definitive classification of adult-type diffuse gliomas, and the NOS category should be reserved only for situations where testing truly cannot be performed.
Key Paradigm Shifts in WHO 2021
- Molecular trumps histology: An IDH-wildtype diffuse astrocytoma (histologically grade 2) is reclassified as glioblastoma grade 4 if it harbors specific molecular features
- Grading within type: Grades are now assigned within each tumor type rather than across types — a grade 3 astrocytoma and a grade 3 oligodendroglioma are biologically very different entities
- Arabic numerals: WHO grades now use Arabic numerals (1, 2, 3, 4) instead of Roman numerals (I, II, III, IV)
- Elimination of “GBM, IDH-mutant”: The term glioblastoma is now reserved exclusively for IDH-wildtype tumors; IDH-mutant grade 4 gliomas are called “astrocytoma, IDH-mutant, grade 4”
- New entities recognized: Diffuse midline glioma H3K27-altered, diffuse hemispheric glioma H3 G34-mutant, and other molecularly-defined pediatric-type gliomas
The Three Adult-Type Diffuse Gliomas
1. Astrocytoma, IDH-Mutant (Grades 2, 3, 4)
IDH-mutant astrocytomas are defined by the presence of an IDH1 or IDH2 mutation, ATRX loss, and the absence of 1p/19q codeletion. They commonly harbor TP53 mutations (>90%). These tumors arise most frequently in younger adults (median age 30–40 years) and preferentially involve the frontal lobe. On imaging, they appear as T2/FLAIR hyperintense, non-enhancing (grades 2–3) or partially enhancing (grade 4) masses with relatively well-defined borders.
Grading Criteria for IDH-Mutant Astrocytoma
- Grade 2: Low mitotic activity, no microvascular proliferation or necrosis, no CDKN2A/B homozygous deletion
- Grade 3: Significant mitotic activity (≥2–6 mitoses per 10 high-power fields, context-dependent) but no microvascular proliferation or necrosis, no CDKN2A/B homozygous deletion
- Grade 4: Microvascular proliferation and/or necrosis present, OR CDKN2A/B homozygous deletion (regardless of histologic features)
CDKN2A/B Homozygous Deletion
- Homozygous deletion of CDKN2A/B (encoding p16/INK4a and p14/ARF) automatically upgrades an IDH-mutant astrocytoma to grade 4
- This applies even if the tumor is histologically low-grade (grade 2 or 3 by morphology)
- CDKN2A/B deletion is detected by FISH or next-generation sequencing panels
- This molecular grading criterion reflects the aggressive biology and inferior prognosis associated with this deletion
2. Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted (Grades 2, 3)
Oligodendrogliomas are defined by the co-occurrence of IDH1/2 mutation and whole-arm 1p/19q codeletion. They retain ATRX expression (in contrast to IDH-mutant astrocytomas) and commonly harbor TERT promoter mutations and CIC mutations. These tumors typically present in the frontal lobe of adults aged 40–60 years and have the best prognosis among adult-type diffuse gliomas, with median survival often exceeding 15–20 years for grade 2 tumors.
Histologically, classic features include “fried egg” perinuclear halos (an artifact of formalin fixation), chicken-wire capillary pattern, and calcification. However, these histologic features alone are neither sufficient nor required for the diagnosis — the molecular signature is definitive.
1p/19q Codeletion: Key Points
- Results from an unbalanced translocation t(1;19)(q10;p10) with loss of the derivative chromosome
- Must involve whole-arm losses of 1p and 19q — partial deletions do not qualify
- Detected by FISH, array CGH, or SNP arrays
- 1p/19q codeletion is mutually exclusive with ATRX loss in practice
- Strongly predictive of response to PCV chemotherapy and alkylating agents
3. Glioblastoma, IDH-Wildtype (Grade 4)
Glioblastoma (GBM) is defined as an IDH-wildtype diffuse astrocytic tumor that is always grade 4. It is the most common and most aggressive primary brain tumor in adults, with a median survival of approximately 14–16 months with standard treatment. GBM predominantly affects older adults (median age 64 years) and typically presents as a ring-enhancing mass with central necrosis and surrounding vasogenic edema.
Molecular Criteria for GBM Diagnosis (Even Without Grade 4 Histology)
- An IDH-wildtype diffuse astrocytic glioma is classified as glioblastoma, grade 4 if any one of the following is present:
- TERT promoter mutation (present in ~80% of GBM)
- EGFR amplification (present in ~40–50%)
- Combined +7/−10 (whole chromosome 7 gain / whole chromosome 10 loss)
- This means a histologically grade 2 or 3 IDH-wildtype astrocytoma with any of these features is reclassified as GBM — these tumors behave clinically as aggressively as conventional GBM
Comparison of Adult-Type Diffuse Gliomas
| Feature | Astrocytoma, IDH-Mutant | Oligodendroglioma, IDH-Mutant & 1p/19q-Codeleted | Glioblastoma, IDH-Wildtype |
|---|---|---|---|
| IDH status | IDH1 or IDH2 mutant | IDH1 or IDH2 mutant | IDH-wildtype |
| 1p/19q codeletion | Absent (intact) | Present (required) | Absent |
| ATRX | Lost (nuclear expression absent) | Retained | Usually retained |
| TP53 | Mutant (>90%) | Usually wildtype | Variable (~30%) |
| TERT promoter | Usually wildtype | Mutant (~95%) | Mutant (~80%) |
| Other key features | CDKN2A/B deletion → grade 4 | CIC, FUBP1 mutations common | EGFR amp, +7/−10, PTEN loss |
| WHO grades | 2, 3, 4 | 2, 3 | 4 (always) |
| Typical age | 30–40 years | 40–60 years | 55–70 years |
| Common location | Frontal lobe, insula | Frontal lobe | Temporal, frontal lobes |
| Imaging | T2/FLAIR hyperintense, minimal enhancement (grade 2–3); ring-enhancing possible (grade 4) | T2/FLAIR hyperintense, calcification, cortical involvement | Ring-enhancing, central necrosis, surrounding edema |
| MGMT methylation | ~60–80% | ~80–90% | ~40–50% |
| Median survival (grade 2) | 10–15 years | 15–20+ years | N/A (always grade 4) |
| Median survival (grade 3–4) | 3–5 years (grade 3); 2–3 years (grade 4) | 10–15 years (grade 3) | 14–16 months |
Key Molecular Markers in Detail
IDH1/IDH2 Mutations
Isocitrate dehydrogenase (IDH) mutations are the most important single biomarker in glioma classification. IDH mutations result in a neomorphic enzyme that converts alpha-ketoglutarate to 2-hydroxyglutarate (2-HG), an oncometabolite that drives epigenetic reprogramming through DNA and histone hypermethylation (the CpG island methylator phenotype, or G-CIMP).
IDH Testing in Practice
- IDH1 R132H immunohistochemistry: Detects the most common mutation (~90% of IDH-mutant gliomas); highly specific and sensitive for this specific variant
- Sequencing required if IHC negative: IDH1 non-R132H variants and all IDH2 mutations (most commonly R172K) require DNA sequencing for detection
- Age consideration: IDH mutations are rare in patients >55 years and in gliomas with typical GBM imaging features; some guidelines allow presumptive IDH-wildtype classification in these cases if IHC is negative
- 2-HG detection by MRS: Magnetic resonance spectroscopy can non-invasively detect elevated 2-HG in IDH-mutant tumors, though this remains a research tool at most centers
MGMT Promoter Methylation
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes alkyl groups from the O6 position of guanine, directly counteracting the cytotoxic effect of temozolomide. Methylation of the MGMT promoter silences gene expression, rendering tumor cells more susceptible to alkylating chemotherapy.
MGMT in Clinical Decision-Making
- Glioblastoma: MGMT methylation is the strongest predictor of temozolomide benefit; methylated GBM has median survival of ~21 months vs. ~14 months for unmethylated with standard Stupp protocol
- Elderly GBM: MGMT status is critical — methylated patients benefit from temozolomide (with or without RT); unmethylated patients may benefit more from radiotherapy alone
- Testing method: Methylation-specific PCR (MSP) or pyrosequencing of CpG islands in the MGMT promoter; IHC for MGMT protein is unreliable and not recommended
- Pseudoprogression: More common in MGMT-methylated GBM (~30% vs. ~10% in unmethylated) — early post-treatment enhancement that mimics progression but represents treatment response
ATRX (Alpha-Thalassemia/Mental Retardation Syndrome X-Linked)
ATRX is a chromatin remodeling protein involved in histone deposition at telomeres. Loss of ATRX expression (detected by IHC) is characteristic of IDH-mutant astrocytomas and is associated with the alternative lengthening of telomeres (ALT) pathway. ATRX loss is mutually exclusive with 1p/19q codeletion in practice, making it a useful surrogate marker to distinguish astrocytomas from oligodendrogliomas when 1p/19q testing is pending.
TERT Promoter Mutations
Telomerase reverse transcriptase (TERT) promoter mutations activate telomerase expression, providing an alternative mechanism for telomere maintenance. They are found in ~95% of oligodendrogliomas and ~80% of IDH-wildtype glioblastomas, but are uncommon in IDH-mutant astrocytomas (which use the ALT pathway via ATRX loss). In the context of an IDH-wildtype diffuse glioma, TERT promoter mutation is one of three molecular criteria sufficient for a grade 4 (GBM) designation.
EGFR Amplification and EGFRvIII
Epidermal growth factor receptor (EGFR) amplification is present in ~40–50% of glioblastomas and is one of the molecular criteria for upgrading an IDH-wildtype glioma to grade 4. The EGFRvIII variant (deletion of exons 2–7) is found in approximately half of EGFR-amplified GBMs and represents a constitutively active receptor. Despite extensive clinical investigation, EGFR-targeted therapies have not shown significant efficacy in GBM to date.
Grading Criteria: Histologic and Molecular
| Tumor Type | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|
| IDH-mutant astrocytoma | Low mitotic activity; no necrosis, no MVP, no CDKN2A/B HD | Increased mitotic activity; no necrosis, no MVP, no CDKN2A/B HD | Necrosis and/or MVP present, OR CDKN2A/B homozygous deletion |
| Oligodendroglioma | Low mitotic activity; no MVP, no necrosis | Increased mitotic activity, and/or MVP, and/or necrosis | Not applicable (no grade 4 oligodendroglioma) |
| GBM, IDH-wildtype | Always grade 4 by definition (histologic or molecular criteria) | ||
MVP = microvascular proliferation; HD = homozygous deletion
Pediatric-Type Diffuse Gliomas
WHO 2021 formally separates pediatric-type gliomas from adult-type gliomas, recognizing their distinct molecular biology and clinical behavior. These are important for neurologists to recognize because they can occasionally present in adults.
Pilocytic Astrocytoma (Grade 1)
The most common pediatric brain tumor, typically arising in the posterior fossa (cerebellar), optic pathway, or hypothalamus. Characterized by BRAF alterations — most commonly the KIAA1549::BRAF fusion (especially in cerebellar tumors) or BRAF V600E point mutation. These are circumscribed, non-infiltrative tumors with an excellent prognosis after surgical resection. BRAF-targeted therapies (dabrafenib, trametinib) are now available for progressive or unresectable cases.
Diffuse Midline Glioma, H3K27-Altered
A highly aggressive tumor defined by H3K27 alteration (either H3K27M mutation in histone H3 variants, or EZHIP overexpression) and a midline location (thalamus, brainstem/pons, spinal cord). These are always WHO grade 4 regardless of histologic appearance. The classic example is diffuse intrinsic pontine glioma (DIPG), which carries a devastating prognosis (median survival <12 months). H3K27M IHC is the standard screening test.
Diagnostic Pitfalls
- Do not diagnose “low-grade glioma” without molecular testing: A histologically bland IDH-wildtype glioma may be a molecular glioblastoma with dismal prognosis
- IDH1 R132H IHC-negative does not mean IDH-wildtype: Non-canonical IDH1 and all IDH2 mutations require sequencing; this is especially important in younger patients
- Partial 1p or 19q deletions are NOT codeletion: Only whole-arm codeletion defines oligodendroglioma; polysomy or partial deletions have different significance
- MGMT IHC is unreliable: Promoter methylation status must be assessed by MSP, pyrosequencing, or methylation arrays — not immunohistochemistry
- H3K27-altered gliomas in adults: While most common in children, these tumors can occur in adults and should be considered for any midline glioma
Integrated Diagnostic Approach
The modern diagnostic workup for a suspected diffuse glioma follows a stepwise molecular evaluation:
| Step | Test | Purpose |
|---|---|---|
| 1 | IDH1 R132H immunohistochemistry | Screen for the most common IDH mutation (~90% sensitivity) |
| 2 | ATRX immunohistochemistry | Loss suggests astrocytoma lineage; retained suggests oligodendroglioma or GBM |
| 3 | p53 immunohistochemistry | Strong diffuse positivity suggests TP53 mutation (astrocytoma) |
| 4 | IDH1/2 sequencing (if IHC negative) | Detect non-canonical IDH1 and IDH2 mutations, especially in patients <55 years |
| 5 | 1p/19q FISH or molecular testing | Confirm codeletion for oligodendroglioma diagnosis |
| 6 | TERT promoter, EGFR, +7/−10 | If IDH-wildtype: determine whether molecular GBM criteria are met |
| 7 | CDKN2A/B FISH | If IDH-mutant astrocytoma: assess for homozygous deletion (upgrades to grade 4) |
| 8 | MGMT promoter methylation | Predict temozolomide response, guide treatment decisions |
| 9 | H3K27M IHC (if midline) | Screen for diffuse midline glioma, H3K27-altered |
Prognostic Stratification
The molecular classification provides a clear prognostic hierarchy for adult-type diffuse gliomas:
Prognostic Hierarchy (Best to Worst)
- Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, grade 2: Median OS >20 years — best prognosis among diffuse gliomas
- Astrocytoma, IDH-mutant, grade 2: Median OS 10–15 years
- Oligodendroglioma, grade 3: Median OS 10–15 years
- Astrocytoma, IDH-mutant, grade 3: Median OS 5–8 years
- Astrocytoma, IDH-mutant, grade 4: Median OS 2–4 years (better than GBM IDH-wt)
- GBM, IDH-wildtype, MGMT-methylated: Median OS ~21 months with standard therapy
- GBM, IDH-wildtype, MGMT-unmethylated: Median OS ~14 months with standard therapy — worst prognosis
Imaging Correlates of Molecular Subtypes
Advances in neuroimaging increasingly allow prediction of molecular status before tissue diagnosis, which can inform surgical planning and prognostic counseling at the time of initial presentation.
Imaging Clues to Molecular Subtype
- IDH-mutant gliomas: Tend to involve the frontal lobe and insula; sharper borders on T2/FLAIR; minimal or no enhancement in grade 2; slower growth rate on serial imaging; 2-HG peak detectable on MR spectroscopy
- IDH-wildtype GBM: Ring-enhancing mass with central necrosis; irregular borders; surrounding vasogenic edema on T2/FLAIR; involvement of temporal and parietal lobes more common; elevated cerebral blood volume (rCBV) on perfusion imaging
- Oligodendroglioma: Cortical-subcortical involvement (tumor extends to cortical surface); calcification visible on CT (~70%); heterogeneous signal on T2; may show “smudgy” enhancement; moderate rCBV elevation
- T2-FLAIR mismatch sign: Homogeneous T2 hyperintensity with FLAIR signal suppression centrally — highly specific (~100%) for IDH-mutant, 1p/19q-intact (i.e., astrocytoma) tumors, though sensitivity is lower (~50%)
- Diffuse midline glioma: Expansile mass in the thalamus, pons, or spinal cord; variable enhancement; may show restricted diffusion
Other CNS Tumor Types of Importance
While the three adult-type diffuse gliomas dominate the neuro-oncology landscape, several other molecularly-defined CNS tumors are important for neurologists to recognize:
| Tumor Type | Key Molecular Feature | WHO Grade | Key Clinical Points |
|---|---|---|---|
| Diffuse midline glioma, H3K27-altered | H3K27M mutation or EZHIP overexpression | 4 | Thalamus, brainstem, spinal cord; includes DIPG; devastating prognosis; ONC201 emerging |
| Diffuse hemispheric glioma, H3 G34-mutant | H3.3 G34R/V mutation | 4 | Cerebral hemispheres of adolescents/young adults; often temporal/parietal |
| Pilocytic astrocytoma | BRAF fusion (KIAA1549::BRAF) or BRAF V600E | 1 | Posterior fossa (children), optic pathway; excellent prognosis with GTR |
| Pleomorphic xanthoastrocytoma (PXA) | BRAF V600E (~70%) | 2 or 3 | Temporal lobe, cortical; young adults; seizures common; BRAF-targetable |
| Ependymoma | ZFTA fusion (supratentorial); YAP1 fusion; PFA/PFB (posterior fossa) | 2 or 3 | Posterior fossa (children), spinal cord (adults); surgery + RT; molecular subgroups predict prognosis |
| Embryonal tumors (medulloblastoma) | WNT, SHH, Group 3, Group 4 subgroups | 4 | Posterior fossa (children); WNT-activated has excellent prognosis (~95% survival); SHH may be targetable |
The Neurologist’s Role in Glioma Diagnosis
While neurosurgeons and neuro-oncologists lead surgical and systemic management, neurologists play a critical role at multiple points in the glioma diagnostic pathway:
- Initial evaluation: Neurologists are often the first specialists to evaluate patients presenting with seizures, progressive headaches, or focal neurologic deficits that lead to imaging and tumor discovery
- Imaging interpretation: Understanding the imaging correlates of molecular subtypes enables informed initial counseling even before pathologic confirmation
- Symptom management: Seizure management, corticosteroid administration, and addressing cognitive and neuropsychiatric symptoms are core neurologic competencies
- Pathology review: Neurologists should be able to interpret the integrated pathology report, understanding the significance of IDH status, 1p/19q codeletion, MGMT methylation, and grading criteria
- Prognostic counseling: Accurate prognostication based on molecular classification is essential for goals-of-care discussions and treatment planning
- Surveillance: Long-term MRI monitoring for treatment response, recurrence, and treatment-related complications (pseudoprogression, radiation necrosis)
Emerging Molecular Targets
The molecular characterization of gliomas has opened new therapeutic avenues:
- IDH inhibitors: Vorasidenib (a dual IDH1/2 inhibitor) demonstrated significant improvement in progression-free survival in the INDIGO trial for grade 2 IDH-mutant gliomas, representing a paradigm shift in treatment of low-grade gliomas
- BRAF inhibitors: Dabrafenib + trametinib for BRAF V600E-mutant gliomas (including pediatric low-grade gliomas)
- DNA methylation profiling: Genome-wide methylation arrays can classify tumors into molecular subgroups with high accuracy, increasingly used as a diagnostic tool (e.g., the Heidelberg classifier)
- Liquid biopsy: Detection of tumor-derived DNA in cerebrospinal fluid or blood is an area of active investigation for diagnosis and monitoring
- CDKN2A/B as a therapeutic target: CDK4/6 inhibitors (palbociclib, ribociclib) are being investigated in CDKN2A/B-deleted gliomas
References
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251.
- Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–608.
- Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186.
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
- Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
- Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–790.
- Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498.
- Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–474.
- Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601.
- Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515–523.
- Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113.
- Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873.